Evidence map›Paper›PMID 40362379›Full record

ArticleInternational journal of molecular sciences2025

Zih-Syuan Wu, Yi-Hsuan Huang, Shih-Ming Huang

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zih-Syuan WuGraduate Institute of Life Sciences, National Defense Medical Center, Taipei City 114, Taiwan.ORCID 0000-0003-3342-4195
Yi-Hsuan HuangGraduate Institute of Life Sciences, National Defense Medical Center, Taipei City 114, Taiwan.ORCID 0000-0003-3350-6879
Shih-Ming HuangGraduate Institute of Life Sciences, National Defense Medical Center, Taipei City 114, Taiwan.ORCID 0000-0001-9305-921X

Funding

Ministry of National Defense-Medical Affairs Bureau, Taiwan, ROC MND-MAB-D-114162 to S.M. HuangTeh-Tzer Study Group for Human Medical Research Foundation, Taipei, Taiwan, ROC A1111035 to S.M. Huang
6 · The paper itself

Abstract

Tramadol, a widely used analgesic, has recently been explored for its potential anti-cancer effects. However, the antitumor dosage of tramadol is over its current clinical application. Its primary metabolite,

Indexed as

Antineoplastic AgentsBreast NeoplasmsReceptors, OpioidTramadolCell Line, TumorCell SurvivalEndoplasmic Reticulum StressFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsAntineoplastic AgentsO-demethyltramadolReceptors, OpioidTramadolbreast cancercytotoxicityER stressO-desmethyltramadolTramadoltumor microenvironmentμ-opioid receptor

Identifiers

PMID40362379
PMCPMC12071290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.